Sven Kili, MD, Antion Biosciences SA, Geneva, Switzerland, provides an overview of the current landscape of autologous and allogeneic cell therapies. Whilst autologous approaches hold potential in delivering personalized therapies for small patient cohorts and rare diseases, allogeneic therapies are expected to become increasingly used in more common indications with larger patient cohorts. Nevertheless, there are still a number of remaining scientific challenges that need to be addressed in order to make large-scale allogeneic approaches a reality, including issues around cell expansion, banking and release criteria. This interview took place at the Advanced Therapies Congress & Expo 2021.
